Clomipramine (Anafranil) in depressive patients with obsessive neurosis.
The authors express the view that, clinically, clomipramine (Anafranil, Geigy Pharmaceuticals) seems to be the treatment of choice for obsessive-compulsive illness. Clomipramine possesses a specific anti-obsessional property which is distinct from its antidepressant property. The optimal therapeutic dose from this study appears to be in the range of 175 mg to 225 mg a day. Minor reversible adverse reaction gradually decreases with the increase of duration of treatment.
D000328:Adult; D002997:Clomipramine / Q000009:adverse effects / Q000627:therapeutic use*; D003863:Depression / Q000188:drug therapy*; D003984:Dibenzazepines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy* / Q000523:psychology
D003984:Dibenzazepines; D002997:Clomipramine